CA
CDLX icon

Crewe Advisors’s Cardlytics CDLX Stock Holding History

Crewe Advisors’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4
Closed -$243 – 848
2022
Q4 		$243 Sell
4
-8
-67% -$494 ﹤0.01% 987
2022
Q3 		$1K Hold
12
– – ﹤0.01% 1119
2022
Q2 		$3K Buy
+12
New +$4.02K ﹤0.01% 875

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GEH
General Equity Holdings Brooklyn, New York $135M AUM 32.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

Crewe Advisors's CDLX Position: Q1 2023 in Review

Crewe Advisors sold out of Cardlytics (CDLX) in Q1 2023, closing a stake of 4 shares — an estimated $243 sold.

Crewe Advisors first reported a position in CDLX in Q2 2022 and held it in 3 quarters. The position peaked at $3K in Q2 2022. 103 funds tracked by Wall St. Rank hold CDLX as of Q1 2023.

  • Crewe Advisors reported no remaining Cardlytics position as of Q1 2023 after selling out during the quarter.
  • Crewe Advisors sold 4 Cardlytics shares in Q1 2023, an estimated $243.
  • Crewe Advisors first reported a position in Cardlytics in Q2 2022 and held it in 3 quarters.
  • Crewe Advisors's Cardlytics position peaked at $3K in Q2 2022.
  • 103 funds tracked by Wall St. Rank held Cardlytics as of Q1 2023.

Based on Crewe Advisors's 13F filing for Q1 2023, filed 12 May 2023.